Development of an Oral Barley Beta-Glucan Adjuvant That Augments the Tumoricidal Activity of Antibodies or Vaccines Used for the Immunotherapy of Breast Cancer

摘要

These Data provided strong evidence for the efficacy of an oral beta- glucan adjuvant for use in combination with anti-tumor antibodies such as Herceptin, Rituxan, and Erbitux. The tumor regression activity of these three antibodies was significantly increased by the simultaneous administration of oral beta-glucan. The data showing that antibodies must activate complement and deposit iC3b on tumors means that antibodies that do not to activate complement would not benefit from oral beta-glucan.